Policy & Regulation
Fresenius and WuXi Biologics agree biosimilars development partnership
2 November 2026 - Healthcare company Fresenius SE & Co KGaA (XETR: FRE) (OTCM: FSNUY) declared on Monday that it has signed an exclusive development agreement with research, development and manufa...
POLYTECH Health & Aesthetics partners with London Regenerative Institute on adipose tissue processing in aesthetic and reconstructive surgery
2 November 2026 - POLYTECH Health & Aesthetics GmbH, a Germany-based company involved in breast aesthetics, reconstruction, and body contouring, and the London Regenerative Institute (LRI), a clin...
Acumen Pharmaceuticals phase 2 Alzheimer's trial misses primary endpoint
30 October 2026 - Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company based in Newton, Massachusetts, on Friday said that initial topline results from its Phase 2 A...
Immunome secures EMA validation of varegacestat application for desmoid tumors
30 October 2026 - Biotechnology company Immunome Inc (Nasdaq:IMNM) announced on Friday that the European Medicines Agency (EMA) has validated its Marketing Authorization Application for varegacestat, ...
FDA approves Sun Pharma's ILUMYA for psoriatic arthritis
30 October 2026 - India-based pharmaceutical company Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) said on Friday that the US Food and Drug Administration (FDA) has approved a su...
Alkermes initiates phase 2 study of ALKS 7290 for major depressive disorder
30 October 2026 - Biopharmaceutical company Alkermes plc (Nasdaq:ALKS) announced on Friday that it has initiated a phase 2 clinical study evaluating ALKS 7290 as an adjunctive treatment for adults wit...